Analysis of acute genitourinary toxicity in hypofractionated proton beam therapy for localized prostate cancer
Abstract
To prospectively determine the incidence of grade 2 acute genitourinary (GU) toxicity after hypofractionated proton beam therapy (PBT) for localized prostate cancer.
The protocol was approved by the institutional review board (IRB). Patients received 51.6 Gy (relative biological effectiveness (RBE)) delivered in 12 fractions over 3 weeks. The primary endpoint was the incidence of grade ≥ 2 acute GU toxicities within 3 months. Neoadjuvant androgen deprivation therapy (ADT) was administered to the intermediate-risk group, and neoadjuvant and adjuvant ADT were administered to high-risk group classified according to the National Comprehensive Cancer Network (NCCN) guideline.
From March 2021 to June 2024, 100 patients underwent hypofractionated PBT. The incidence of grade 2 acute GU toxicities (urinary frequency) was 8% (95% confidence interval [CI] 2.6–13.4), meeting the pre-specified continuation criterion. No grade ≥ 3 acute GU toxicities were observed. Furthermore, no grade ≥ 2 acute urinary retention, urinary pain, urinary urgency or hematuria were observed. Univariate analysis preliminarily suggested that compared with the high-risk group patients, the low- and/or intermediate-risk group patients had a higher trend of grade 2 GU toxicities (OR: 0.265 (95% CI 0.066–1.062), P = 0.055). Multivariate regression analysis further confirmed that the high-risk classification was associated with a significantly lower risk grade 2 GU toxicities (OR: 0.023 (95% CI 0.002–0.840), P =…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.